

**January Meeting Draft
(Effective April 2026)**

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

Purple shade signifies a product either no longer covered (rebtable) or no longer available from the manufacturer

Preferred	Non-Preferred
-----------	---------------

NTM: Added Legembi® Autoinjector to non-preferred

OPIOID ANALGESICS

criteria apply to all drugs in the

	Belbuca® (Buccal) Film
	Abuse Testing Results

Additional utilization management or prior authorization exists

Clinical criteria apply to all drugs in this class	

	Dilaudid [®] Liquid / Tablet
--	---------------------------------------

Scheduling Schedule III – IV Opioids / Analgesic Combination	
1	100 mg/6.25 mg
2	100 mg/12.5 mg
3	100 mg/25 mg
4	100 mg/50 mg
5	100 mg/100 mg
6	100 mg/200 mg
7	100 mg/400 mg
8	100 mg/800 mg
9	100 mg/1600 mg
10	100 mg/3200 mg
11	100 mg/6400 mg
12	100 mg/12800 mg
13	100 mg/25600 mg
14	100 mg/51200 mg
15	100 mg/102400 mg
16	100 mg/204800 mg
17	100 mg/409600 mg
18	100 mg/819200 mg
19	100 mg/1638400 mg
20	100 mg/3276800 mg
21	100 mg/6553600 mg
22	100 mg/13107200 mg
23	100 mg/26214400 mg
24	100 mg/52428800 mg
25	100 mg/104857600 mg
26	100 mg/209715200 mg
27	100 mg/419430400 mg
28	100 mg/838860800 mg
29	100 mg/1677721600 mg
30	100 mg/3355443200 mg
31	100 mg/6710886400 mg
32	100 mg/13421772800 mg
33	100 mg/26843545600 mg
34	100 mg/53687091200 mg
35	100 mg/107374182400 mg
36	100 mg/214748364800 mg
37	100 mg/429496729600 mg
38	100 mg/858993459200 mg
39	100 mg/1717986918400 mg
40	100 mg/3435973836800 mg
41	100 mg/6871947673600 mg
42	100 mg/13743895347200 mg
43	100 mg/27487790694400 mg
44	100 mg/54975581388800 mg
45	100 mg/109951162777600 mg
46	100 mg/219902325555200 mg
47	100 mg/439804651110400 mg
48	100 mg/879609302220800 mg
49	100 mg/1759218604441600 mg
50	100 mg/3518437208883200 mg
51	100 mg/7036874417766400 mg
52	100 mg/14073748835532800 mg
53	100 mg/28147497671065600 mg
54	100 mg/56294995342131200 mg
55	100 mg/112589990684262400 mg
56	100 mg/225179981368524800 mg
57	100 mg/450359962737049600 mg
58	100 mg/900719925474099200 mg
59	100 mg/1801439850948198400 mg
60	100 mg/3602879701896396800 mg
61	100 mg/7205759403792793600 mg
62	100 mg/14411518807585587200 mg
63	100 mg/28823037615171174400 mg
64	100 mg/57646075230342348800 mg
65	100 mg/115292150460684697600 mg
66	100 mg/230584300921369395200 mg
67	100 mg/461168601842738790400 mg
68	100 mg/922337203685477580800 mg
69	100 mg/1844674407370955161600 mg
70	100 mg/3689348814741910323200 mg
71	100 mg/7378697629483820646400 mg
72	100 mg/14757395258967641292800 mg
73	100 mg/29514790517935282585600 mg
74	100 mg/59029581035870565171200 mg
75	100 mg/118059162071741130342400 mg
76	100 mg/236118324143482260684800 mg
77	100 mg/472236648286964521369600 mg
78	100 mg/944473296573929042739200 mg
79	100 mg/1888946593147858085478400 mg
80	100 mg/3777893186295716170956800 mg
81	100 mg/7555786372591432341913600 mg
82	100 mg/15111572745182864683827200 mg
83	100 mg/30223145490365729367654400 mg
84	100 mg/60446290980731458735308800 mg
85	100 mg/120892581961462917470617600 mg
86	100 mg/241785163922925834941235200 mg
87	100 mg/483570327845851669882470400 mg
88	100 mg/967140655691703339764940800 mg
89	100 mg/1934281311383406679529881600 mg
90	100 mg/3868562622766813359059763200 mg
91	100 mg/7737125245533626718119526400 mg
92	100 mg/15474250491067253436239052800 mg
93	100 mg/30948500982134506872478105600 mg
94	100 mg/61897001964269013744956211200 mg
95	100 mg/123794003928538027489912422400 mg
96	100 mg/247

Clinical criteria apply to all drugs in this class

Additional utilization management or prior authorization criteria may apply.

--	--

Preferred

	Arthrotec® Tablet
	®

NTM: Added Lurbico™ Tablet to non-preferred

--	--

	DermacinRx™ Lidocain Patch
	Dolonec™ Emulgel

ANTICONVULSANTS

**January Meeting Draft
(Effective April 2026)**

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

Patients with a diagnosis of seizure disorder are exempt from T/F criteria and may use any carbamazepine product.

[illegible]

**January Meeting Draft
(Effective April 2026)**

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

[illegible]

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)
January Meeting Draft
(Effective April 2026)

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL, effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

		ProComp® Solution Quibron® Capsule Quilbeson® ER Tablet - T/F of preferred agents not required for children < 12 years of age Quilam® XR Suspension - T/F of preferred agents not required for children < 12 years of age Relerex® ER Tablet Ritalin® LA Capsule Ritalin® Tablet Statteron® Capsule Vyvanse® Chewable Tablet Xelstron® Patch Zenox® Tablet		
INJECTABLE ANTIPSYCHOTICS				
Injectable Long Acting				
Preferred	Pharm may not apply additional utilization management or prior authorization criteria to this category		Non-Preferred	
Abilify Asimetric® Syringe Kit Abilify Maintena® Syringe / Vial Aristada® Tablet / Syringe Eradont® (paliperidone palmitate) extended-release injectable suspension Euphlexone decanoate vial (generic for Prolixin decanoate®) Haldol® decanoate Ampule Indegardol decanoate ampule / vial (generic for Haldol decanoate®) Invega® Heflexa Prefilled Syringe Kit Invega® Sustenna Prefilled Syringe Invega® Trintra Syringe Persero® Syringe Risperidol® Consta Vial Seroquel® XR vial (generic for Risperidol® Consta) Sylvestra® Vial / Vial Kit Utopia® Syringe Kit Zyprexa® Relapsers® Vial Kit				
ATYPICAL ANTIPSYCHOTICS				
Oral / Transdermal				
Preferred	Pharm may not apply additional utilization management or prior authorization criteria to this category T/F of only one preferred drug required		Non-Preferred	
aripiprazole Tablet / Solution (generic for Abilify®) lurasidone SR tablet (generic for Luthena® SR) clozapine tablet (generic for Clozaril®) lurasidone tablet (generic for Latuda®) olanzapine ODT / tablet (generic for Zyprexa®) melperone ER tablet (generic for Invega®) aripiprazole tablet / ER tablet (generic for Strattera® / XR) aripiprazole ODT / solution / tablet (generic for Strattera®) Vencor® Capsule aprepitant capsule (generic for Glaxo®)		Abilify® Tablet / Abilify® M/Cin® Tablet aripiprazole ODT (generic for Abilify® Decanoate®) Caplan® Capsule clozapine ODT (generic for Faneca®) Clozapin® Tablet Clozinet® Colony® Starter Pack Faneca® Tablet / Transdermal Patch Glaxo® Capsule Invega® Tablet Luthena® Tablet Luthena® Tablet Nuplatin® Tablet / Capsule olanzapine-fluoxetine capsule (generic for Stridocin®) Zyprexa® (Aripiprazole) Oral Film Risperal® Tablet / 7-Day Pack / 14-Day Pack Risperidol® Solution / Tablet Saphin® SR Tablet Seroquel® Patch Seroquel® Tablet / XR Tablet / XR Sample Kit Vencorin® Suspension Zyprexa® Tablet / Zyplo® Tablet		
CARDIOVASCULAR				
ACE INHIBITORS				
Preferred			Non-Preferred	
lisinopril tablet (generic for Lotensin®) enalapril tablet (generic for Vasotec®) lisinopril tablet (generic for Presto® and Zeval®) captopril capsule (generic for Alcap®)		Alcap® Tablet Alcap® Capsule captopril tablet (generic for Capoten®) captopril solution (generic for Capoten®) - T/F of preferred agents not required for children < 12 years of age Enalapril® Solution - T/F of preferred agents not required for children < 12 years of age lisinopril tablet (generic for Monopril®) lisinopril Tablet lisinopril tablet (generic for Vasotec®) perindopril tablet (generic for Accova®) Quebec® Solution - T/F of preferred agents not required for children < 12 years of age lisinopril tablet (generic for Accupro®) trandolapril tablet (generic for Mithril®) Zoval® Tablet		
ACE INHIBITOR / CALCIUM CHANNEL BLOCKER COMBINATIONS				
Preferred			Non-Preferred	
amlodipine-benazepril capsule (generic for Lotrel®)		Lotrel® Capsule trandolapril-comenzel ER tablet (generic for Tarka®)		
ACE INHIBITOR / DIURETIC COMBINATIONS				
Preferred			Non-Preferred	
enalapril-HCTZ tablet (generic for Vasotec®) lisinopril-HCTZ tablet (generic for Presto®, Zevalin®, Zevalin®)		Accupro® Tablet lisinopril-HCTZ tablet (generic for Lotensin® HCT) captopril-HCTZ tablet (generic for Capoten®) lisinopril-HCTZ tablet (generic for Monopril® HCT) Lotensin® HCT Tablet enalapril-HCTZ tablet (generic for Accupro®, Optenac®) Vasotecin® Tablet Zovalin® Tablet		
ANGIOTENSIN II RECEPTOR BLOCKERS				
Preferred	NTM: Added Arbli® Suspension to non-preferred		Non-Preferred	
valsartan tablet (generic for Avapro®) losartan tablet (generic for Cozaar®) telmisartan tablet (generic for Micardis®) valsartan tablet (generic for Diovan®)		AAAP® Suspension Atacand® Tablet Atacand® Tablet Benazepril® Tablet canesartan tablet (generic for Atacand®) Cozaar® Tablet Diovan® Tablet Edarby® Tablet canesartan tablet (generic for Teveton®) Micardis® Tablet telmisartan tablet (generic for Micardis®) telmisartan oral solution		
ANGIOTENSIN II RECEPTOR BLOCKER COMBINATIONS				
Preferred			Non-Preferred	
amlodipine-valsartan tablet (generic for Atran®) amlodipine-valsartan tablet (generic for Evolog®) amlodipine-valsartan-HCTZ tablet (generic for Telvasin®)		Atran® Tablet Evolog® Tablet / HCT Tablet telmisartan-amlodipine tablet (generic for Tevasin®) Telvasin® Tablet amlodipine-valsartan-HCTZ tablet (generic for Telolog® HCT)		
ANGIOTENSIN II RECEPTOR BLOCKER / DIURETIC COMBINATIONS				
Preferred			Non-Preferred	
valsartan-HCTZ tablet (generic for Avsolv®) losartan-HCTZ tablet (generic for Hyman®) valsartan-HCTZ tablet (generic for Diovan® HCT) valsartan-HCTZ tablet (generic for Diovan® HCT)		Atacand® HCT Tablet Avsolv® Tablet Benazepril® HCT Tablet canesartan-HCTZ tablet (generic for Atacand® HCT) Diovan® HCT Tablet Edarbyclor® Tablet Hyman® Tablet Micardis® HCT Tablet telmisartan-HCTZ tablet (generic for Micardis® HCT)		
ANGIOTENSIN II RECEPTOR / NEPRILYSIN BLOCKER COMBINATIONS				
Preferred	Pharm may not apply additional utilization management or prior authorization criteria to this category		Non-Preferred	
Entresto® Tablet		Entresto® (sacubitril) / valsartan Sprinkle Pellets-T/F of preferred agents not required for children < 12 years of age sacubitril and valsartan tablet (generic for Entresto®)		
ANTIANGINAL & ANTI-ISCHEMIC				
Preferred			Non-Preferred	
nitroglycerin ER tablet (generic for Nitrostat® Tablet)		Aspirin® Sprinkle		
ANTIARRHYTHMICS				
Preferred			Non-Preferred	
propafenone tablet (generic for Propafenone®) disopyramide capsule (generic for Norpace®) dofetilide capsule (generic for Tikosyn®) flecainide tablet (generic for Tambocor®) sotalone capsule (generic for Misoctin®) propafenone tablet (generic for Rhythol®) propafenone SR capsule (generic for Rhythol SR®) sotalone tablet (generic for Sotacor® Tablet)		Misone® Tablet Norpace® Capsule / CR Capsule Procumene® Tablet Sotalone® Tablet sotalone propafenone ER tablet (generic for Quinagilide Duet2ab®) Tikosyn® Capsule		
BETA BLOCKERS				
Preferred	Pharm may not apply additional utilization management or prior authorization criteria to this category		Non-Preferred	
atenolol tablet (generic for Tenormin®) bisoprolol tablet (generic for Zibeta®) carvedilol tablet (generic for Coreg®) bisoprolol Solution		acetylsalicylic capsule (generic for Asprin®) Bisoprolol® Tablet / AT Tablet bisoprolol tablet (generic for Kerlone®) Bystolic® Tablet		

**January Meeting Draft
(Effective April 2026)**

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

[illegible]

**January Meeting Draft
(Effective April 2026)**

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

[illegible]

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL, effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED.** For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

Page 7 of 15

January Meeting Draft (Effective April 2026)

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

		Zovexim XR Tablets	
		Zovira® Tablets	
	Preferred	Meglidine	Non-Preferred
azacitidine tablet (generic for Azacita®)			
azacitidine tablet (generic for Pandina®)			
		SGLT-2 Inhibitors and Combinations	
		Plans may not apply additional utilization management or prior authorization criteria to this category	
		Clinical criteria apply to all drugs in this class	
	Preferred		Non-Preferred
Farxiga® Tablet		dapagliflozin tablet (generic for Farxiga®)	
FarxigaXR® Tablet		dapagliflozin / metformin ER tablet (generic for Xigduo® XR)	
Glyxambi® Tablet		Jardiance® Tablet	
Glyxambi® XR Tablet		liraglutide Tablets / XR Tablet	
Stavio® XR Tablet		saxagliptin Tablet	
		saxagliptin / metformin Tablet	
		sitagliptin Tablet	
		Thiazolidinediones and Combinations	
	Preferred		Non-Preferred
pioglitazone tablet (generic for Actos®)		ActoPlus Met® Tablet	
		Actos® Tablet	
	Open class-No recommendations	Duractin® Tablet	
		rosiglitazone-alimemazine tablet (generic for Duractin®)	
		rosiglitazone-metformin tablet (generic for ActoPlus Met®)	
		GASTROINTESTINAL	
		ANTIEMETIC-ANTIVERTIGO AGENTS	
		Plans may not apply additional utilization management or prior authorization criteria to this category	
	Preferred		Non-Preferred
aperient capsule (generic for Enoxal®) - Clinical criteria apply		Akronox® Capsule / Vial	
Decligan® Tablet		Anivert® Tablet / Chewable Tablet	
ondansetron tablet (generic for Anivert®)		Anivert® Tablet	
ondansetron suspension / tablet (generic for Ryolan®)		Axonox® Vial	
ondansetron ODT 4mg and 8 mg solution / tablet (generic for Zedran®)		aperient pack (generic for Enoxal®) - Clinical criteria apply	
ondansetron tablet (generic for Compensat®)		Budonox® Vial	
ondansetron syrup / suspension (17.5 mg and 25 mg) / tablet / sample / vial (generic for Phenergan®)		Bugista® Tablet	
Phenergan® (promethazine) Suppositories (17.5 mg and 25 mg)		Cicurate® Vial	
promethazine tablets (generic for Transdom-Sleep®)		Cimetidine Suspension	
Transdom-Sleep® Patch		dicyclanate oral (generic for Dramamine®)	
		doxylamine-erythromycin tablet (generic for Diclamin®)	
		dramamine capsules (generic for Dramamine®)	
		Enoxal® Capsule / Powder Packet / Tablet Pack - Clinical criteria apply	
		Enoxal® Vial	
		Pacirox® (Etoproxifen) Vial	
		isopropant vial (generic for Enoxal®)	
		Simoni® Nasal Spray	
		granisetron vial / tablet (generic for Kytil®)	
		Motil® Capsule	
		ondansetron vial	
		ondansetron ODT (16 mg)	
		ondansetron vial	
		ondansetron injection (generic for Akron®)	
		Phenergan® Ampule / Vial	
		Pocitra™ V Vial	
		prochlorperazine vial / suppository (generic for Compensat®)	
		Prochlorperazine Suppositories (25 mg)	
		Ryolan® Tablet	
		Sereno® Patch	
		Sustol® Syringe	
		Tamox® Vial	
		tetracycline hydrochloride capsules (generic for Tams®)	
		BILE ACID SALTS	
		VF of only one preferred drug required	
	Preferred		Non-Preferred
cholesterol capsule (generic for Actoval®)		Bilevel® Capsule / Pellet - VF of preferred agents not required for diagnosis of PBC	
cholesterol tablet (generic for Umo®)		Cholesterol® Tablet	
		Cholestol® Capsule	
		Cosol® Tablet	
		heparin® (calciferous) Tablet	
		Lindole Capsule	
		Lipomel® Oral Solution / Tablet	
		Oxalval® Tablet	
		Reflux® Capsule	
		Umo® Tablet	
		H. PYLORI COMBINATIONS	
	Preferred		Non-Preferred
Pylori® Capsule		Nasimid® / metronidazole / tetracycline capsule (generic for Pylori®)	
		metronidazole-amoxicillin-clarithromycin-pylori (generic for Pylori®)	
		Quercetin-Pylori® Combo Pack	
		Talcia® Capsule	
		Vaccines® Tablet / Dual Pak / Triple Pak	
		HISTAMINE-2 RECEPTOR ANTAGONISTS	
	Preferred		Non-Preferred
fexofenadine tablet / suspension (generic for Fexofast®)		cetirizine tablet (generic for Tanum®)	
	Open class-No recommendations	cetirizine capsules (generic for Tanum®)	
		cetirizine solution (generic for Tanum®)	
		fenistyle capsules (generic for Aten®)	
		PANCREATIC ENZYMES	
		Plans may not apply additional utilization management or prior authorization criteria to this category	
	Preferred		Non-Preferred
Creon® Capsule		Creonix® Capsule	
Viokase® Tablet			
Zymore® Capsule			
	P	PROGESTINS USED FOR CACHEXIA	Non-Preferred
megestrol suspension / tablet (generic for Megace® ES)		megestrol ES suspension (generic for Megace® ES)	
	Preferred		Non-Preferred
		PROTON PUMP INHIBITORS	
		VF of preferred agents not required for children < 12 years of age	
esomeprazole magnesium capsule (generic for Nexium® Rx)		Debidol® Capsule	
esomeprazole capsules (generic for Protonix® Rx)		esomeprazole capsules (generic for Debidol®)	
Nexium® Rx Packet		esomeprazole magnesium (OTC) capsule / tablet (generic for Nexium® OTC)	
esomeprazole Rx capsule (generic for Protonix® Rx)		esomeprazole magnesium packet (generic for Nexium® Rx Packet)	
esomeprazole tablet (generic for Protonix®)		Kemover® Suspension	
Protonix® Suspension		esomeprazole capsules (generic for Protonix® OTC)	
		esomeprazole ODT (generic for Protonix® Sublet®)	
		NALMIX® Rx Capsule	
		esomeprazole OTC capsule / ODT / tablet (generic for Protonix® OTC)	
		esomeprazole sodium bicarbonate capsule / packet (generic for Zegerid® Rx / OTC)	
		esomeprazole suspension (generic for Protonix®)	
		Protonix® Rx OTC Capsule / Tablet	
		Protonix® Rx Suspension	
		Protonix® Tablet	
		esomeprazole tablet (generic for Acibel®)	
		SELECTIVE CONSTIPATION AGENTS	
	Preferred		Non-Preferred
Liprox® Capsule		absetron tablet (generic for Loprox®)	
lubiprostone capsule (generic for Amitiza®)		Amitiza® Capsule	
		Bardol® Tablet	
		Calvelex® Tablet	
		Metacarb® Tablet	
		Metocarb® Tablet	
		metocarbamide tablet (generic for Metocarb®)	

**January Meeting Draft
(Effective April 2026)**

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

[illegible]

**January Meeting Draft
(Effective April 2026)**

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

TiF criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED.** For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

Real MMS [®] Drops prednisolone acetate drops (generic for Pred Forte [®])		Revas [®] Implant levodopa [®] Drops Arthroflex solution (generic for Anelarth [®] 150) Lofemex [®] Cell / 90 Cell [®] Capsules Interspedal Drops / gel (generic for Lofemex [®]) Maxiset [®] Drops Ozurdex [®] Implant Paul Frost [®] Drops prednisolone sodium phosphate drops (generic for Inflammase Forte [®]) Profema [®] Drops Retisert [®] Implant Trexone [®] Vial Super [®] (Intravitreal) Yutop [®] Implant	
ANTI-INFLAMMATORY / IMMUNOMODULATOR <i>Plans may not apply additional utilization management or prior authorization criteria to this category</i>			
Preferred Revas [®] Drops Nixida [®] Drops		Non-Preferred Cyclo [®] Drops cyclosporine emulsion (generic for Revas [®]) Eyaxia [®] Drops Mabis [®] Drops Revas [®] Multidose [™] Drops Trexone [®] Drops Trexone [®] Nasal Spray Valsone [®] Eye Emulsion - T/P of preferred agents not required for diagnosis of central keratoepitheliitis (CKE) Xecur [®] Drops	
Preferred Alpha [®] P Drops brominamide drops (generic for Alpha [®])		Non-Preferred ALPHA 2 ADRENERGIC AGENTS brominamide drops (generic for Alphagan [®]) brominamide P drops (generic for Alphagan [®] P) Ista [®] Drops	
Preferred Combi [®] Drops timolol drops / GFS gel solution (generic for Timoptic [®] / Timoptic XL [®])		Non-Preferred BETA BLOCKER AGENTS / COMBINATIONS betaxolol drops (generic for Betoptic [®]) Betina [®] Drops Betoptic [®] S Drops brominamide tartrate / timolol drops (generic for Combina [®]) carteolol drops (generic for Ocuvant [®]) Ista [®] Drops timololamide drops (generic for Betagan [®]) timolol brominamide (generic for Betimol [®] drops) timolol drop (generic for Ista [®] Drops) timolol maleate drop (generic for Timoptic [®] / Ocuvant [®] Drops) Discontinued Drops: XE[®] Solution Ocuvant [®] Drops	
Preferred Acuvant [®] Drops diclofenac drops (generic for Travert [®]) diclofenac timolol drops (generic for Comb [®]) Hecavan [®] Drops		Non-Preferred CARBONIC ANHYDRASE INHIBITORS / COMBINATIONS Acuvant [®] Drops timololamide drops (generic for Alphagan [®] P) Ista [®] Drops timololamide timolol P drops (generic for Comb [®] P) Ocuvant [®] Drops	
Preferred Latamovet drops (generic for Xalatan [®]) Travert [®] Z Drops		Non-Preferred PROSTAGLANDIN AGONISTS timololamide drops (generic for Latamovet [®] Drops) Travert [®] Implant Dose [®] TR Implan Dose [®] Drops Lumigan [®] Drops allergan drops (generic for Travert [®]) latanoprost drops (generic for Travert [®] P) Viaside [®] Drops Xalatan [®] Drops Xalatan [®] Drops Zalatan [®] Drops Zalatan [®] Drops	
RHO KINASE MODIFIERS / COMBINATIONS <i>Plans may not apply additional utilization management or prior authorization criteria to this category</i>			
Preferred Brimonid [®] Drops Brimonid [®] Drops		Non-Preferred	
OSTEOPOROSIS BONE RESORPTION SUPPRESSION AND RELATED AGENTS			
Preferred Acuvant [®] Tablet (generic for Fosamax [®]) Biphon [®] Syringe (Prefill [®] Biphon) Lortin [®] Piv calcitonin tablet (generic for Evista [®])		Non-Preferred Acuvant [®] Tablet Acuvant [®] solution (generic for Fosamax [®] Solution) Acuvant [®] Tablet Biphon [®] Effervescent Tablet Biphon [®] Pen Syringe calcitonin sodium nasal spray (generic for Miacalcin [®]) Conexence[®] Syringe (Prefill[®] Biphon) Evista [®] Syringe Evista [®] Tablet Fosamax [®] Tablet / Plus D Tablet Fosamax [®] Tablet (generic for Biphon [®]) Lortin [®] Syringe (Prefill [®] Biphon) Lortin [®] Syringe (Prefill [®] Biphon) Lortin [®] Syringe Lortin [®] DR tablet (generic for Acuvant [®]) Lortin [®] tablet (generic for Acuvant [®]) Lortin [®] Syringe (Prefill [®] Biphon) Lortin [®] pen (generic for Lortin [®]) Lortin [®] Pen	
Preferred Acuvant [®] Tablet (generic for Fosamax [®]) Acuvant [®] Tablet (generic for Fosamax [®]			

**January Meeting Draft
(Effective April 2026)**

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL, effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

T/F criteria, clinical criteria (indicated in **RED**) may also apply. New to market products typically default to Non-Preferred status until

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

INHALED CORTICOSTEROIDS

Plans may not apply additional utilization management or prior authorization criteria to this category

Preferred	Non-Preferred
Albuterol^o Inhaler NTM: Added fluticasone furoate Inh (generic for Arnuity Ellipta^o) to non-preferred Arnuity^o Ellipta^o Inhaler Arnuity^o HFA Inhaler / Turbuhaler^o Obsolete: Removed Flovent^o Diskus / HFA Inhaler Endobronchial nebulizer 0.5mg, 0.5mg, 1mg (generic for Pulmicort^o Budesonide) Obsolete: Albuterol Inhaler Diskus	Arnuity^o Turbuhaler^o Budesonide Furoate DPI (generic for Arnuity Ellipta^o) Budesonide Furoate Diskus (generic for Flovent^o Diskus) Budesonide nebulizer diskus (generic for Flovent^o Diskus) Budesonide Nebulizer 0.5mg, 0.5mg, 1mg

INHALED CORTICOSTEROID COMBINATIONS

Plans may not apply additional utilization management or prior authorization criteria to this category

	Preferred	Non-Preferred
Adjuvax [®] Duetron [™]	AdDuo [®] Duetron [™] / RecombiCell [™]	
Adjuvax [®] HPA Inhibitor	AdOptima [®] Inhibitor	
Duetron [™] Inhibitor	Bion [®] Elipha [™]	
Gardasil [®] Inhibitor	Hecron [®] Inhibitor	
	Hecon [®] Aurophage [™]	
	Infectomune [®] Intranasal adjuvant (generic for Novartis) ^(*)	
	Relicovene [®] / subcutaneous HPA inhibitor (generic for Adjuvax [®] /HPA)	
	Relicovene [®] / intradermal adjuvant (generic for Adjuvax [®] /Duetron [™])	
	Relicovene [®] / subcutaneous adjuvant (generic for AdDuo [®])	
	Relicovene [®] / intradermal adjuvant (generic for Bion [®] Elipha [™])	
	Vaccine [™] Filled	
	Wachter [™] Inhib [™]	

INTRANASAL RHINITIS AGENTS

[illegible]

LEUKOTRIENE MODIFIERS

Preferred	Non-Preferred
metololactate chewable / tablet (generic for Singulair [®])	Accolate [®] Tablet
	metololactate granules (generic for Singulair [®])
	Singulair [®] 2 Chewable / Granules / Tablet
	paliperidone tablet (generic for Accolate [®])
	olmesartan tablet (generic for Zylis [®])
	Zylis [®] Filmtab

LOW SEDATING ANTIHISTAMINES

--	--

acetaminophen OTC syrup 1mg/1ml (syrup for Zimtec® OTC Syrup) acetaminophen Rx syrup (generic for Zimtec® Syrup) acetaminophen tablets OTC (generic for Zimtec® OTC Tablet) acetaminophen OTC tablet (generic for Xyzal® OTC Tablet) acetaminophen Rx tablet (generic for Xyzal® Rx Tablet) fenofibrate tablet OTC (generic for Chantrel® OTC)	acetaminophen chewable tablet OTC (generic for Zimtec® OTC Tablet) acetaminophen OTC syrup 5mg/5ml (generic for Zimtec® OTC Syrup) acetaminophen OTC tablet Chantrel® Tablets - TB of unfurfurated agents not required for children < 2 years of age fenofibrate OTC Tablet (generic for Chantrel®) - TB of unfurfurated agents not required for children < 2 years of age fenofibrate OTC suspension (generic for Chantrel®) - TB of unfurfurated agents not required for children < 2 years of age fenofibrate Rx solution (generic for Xyzal® Rx Solution) fenofibrate Rx chewable ODT / solution (generic for Chantrel® OTC)
--	--

LOW SEDATING ANTIHISTAMINE COMBINATIONS

Plans may not apply additional utilization management or prior authorization criteria to this category

Quantity limit of 102 days supply per 12 months apply to all drugs in this class

PROTECTUS	NON-PROTECTUS
fenofibrate-D OTC tablet (generic for Claritin-D [®] OTC)	cetirizine-D OTC tablet (generic for Zyrtec-D [®] OTC)
	Chlorazep-D [®] Tablet
	fenofibrate-D 12 Hour OTC Tablet (generic for Allergo-D [®] 12 Hour OTC)
	fenofibrate-pseudoephedrine ER-24 hour tablet (generic for Allergo-D [®] 24 hour)

FIRST GENERATION ANTIHISTAMINES

Preferred	Non-Preferred
carbamazepine solution	carbamazepine tablet
Carbasa® Solution	Carbamazepine tablet (generic for Clevonia™)
cyclophosphamide vialcap / tablet	Clemsta® Tablet
hydroxyzine capsule / solution / tablet	Carbasa® EP Suspension - 1/2 of immediate release carbamazepine solution and cefixime vialcap required for co-prescription
	RivCera® Solution
	RivVent® Tablet

TOPICALS

ACNE AGENTS

[illegible]

ANDROGENIC AGENTS

Preferred	Non-Preferred
AndroGel® Pump testosterone gel pump (generic for AndroGel®)	AndroGel® Packet Nasarel® Nasal Gel Testim® Gel testosterone gel pump (generic for Testim®; <i>AndroGel®</i>) testosterone patch (generic for AndroGel®) Vyachel® Gel / Packet / Pump
Obsolete: Removed AndroGel® Packet	

NSAIDS

Preferred	Non-Preferred
<code>dictdefns: typical: argens: for Volume⁸ Grid</code>	<code>dictdefns: excludant: patch: argens: for PVector⁹</code>
<code>dictdefns: solution: argens: for Permaoff¹⁰</code>	<code>dictdefns: pump: argens: for Permaoff¹¹</code>
	<code>Permaoff¹² Solution Packer - Pump</code>

ANTIBIOTICS

Preferred	Non-Preferred
gentamicin cream / ointment (generic for Gentamicin [®])	Centany [®] AT Ointment Kit / Ointment

**January Meeting Draft
(Effective April 2026)**

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

reviewed by the PDL Panel. These drugs are listed as **TO BE REVIEWED**. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>

[illegible]

**January Meeting Draft
(Effective April 2026)**

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

NTM: Added Otezla® XR Initiation Pack / Tablet and Avtozma® Vial to non-preferred
Off Cycle change: Moved Pyszchiva® Syringe/Vial and Steqeyma® Vial /Syringe from non-preferred to preferred
Off Cycle change: Added red writing to Stelara® Syringe / Vial **T/F of preferred usteknumab is required**
Reconciliation: Added adalimumab-aacP Psoriasis-UV Pen / Crohn's Pen / Syringe to non-preferred

**January Meeting Draft
(Effective April 2026)**

1/f- criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED.** For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

Page 14 of 15

North Carolina Division of Health Benefits
North Carolina Medicaid Preferred Drug List (PDL)
**January Meeting Draft
(Effective April 2026)**

Revised 12.10.2025 Off Cycle Change: GLP-1 weight management class added to the PDL, effective 10.01.2025. See clinical criteria for coverage.

Trial and failure (T/F) of two Preferred drugs are required unless only one Preferred option is listed or a T/F criteria exemption is otherwise indicated.

Not all therapeutic drug classes are included on the PDL. All drugs in the classes not included are considered Preferred. In addition to T/F criteria, clinical criteria (indicated in **RED**) may also apply. **New to market products typically default to Non-Preferred status until**

reviewed by the PDL Panel. These drugs are listed as TO BE REVIEWED. For drugs requiring prior authorization, clinical criteria and prior authorization request forms can be found at: <https://www.nctracks.nc.gov/content/public/providers/pharmacy.html>
More information on the PDL can be found at: <https://medicaid.ncdhhs.gov/providers/programs-services/prescription-drugs/outpatient-pharmacy-services>

FreeStyle Libre™ 2 Reader	
FreeStyle Libre™ 3 Reader	
Continuous Glucose Monitor Sensors	
Plans may not apply additional utilization management or prior authorization criteria to this category.	
Clinical criteria apply to all items in this class	
Preferred	Non-Preferred
FreeStyle Libre™ 2 Sensor	FreeStyle Libre™ 14 day Sensor
FreeStyle Libre™ 2 Plus Sensor	
FreeStyle Libre™ 3 Sensor	
FreeStyle Libre™ 3 Plus Sensor	
Dexcom G7® Sensor	
Dexcom G7® Sensor (10 day sensor and 15 day sensor)	
DIABETIC SUPPLIES	
Plans may not apply additional utilization management or prior authorization criteria to this category.	
N.C. Medicaid only covers, at point of sale, the designated preferred products listed below for blood glucose meters, diabetic test strips, control solutions, lancets, and lancing devices for Medicaid primary recipients (dualy eligible and third-party recipients are not affected). These products are covered under the Outpatient Pharmacy Program and can be submitted to the pharmacy point-of-sale system with a prescription. Diabetic supplies, including other brands, can also be submitted under Durable Medical Equipment using the NDC and HCPCS code. Beneficiaries are allowed 1 covered meter every 2 years (730 days). For questions or assistance regarding diabetic supplies for Medicaid Direct members, please call the NC Tracks call center at 1-800-688-6696. *All blood glucose meters are billed using the NC Medicaid Free BIN Meter program. BIN 610524, PCN 1016, Group 40026479, ID 066499643.*	
Meters	Lancing Devices
ACCU-CHEK® Guide Retail care kit * (see above for billing)	ACCU-CHEK® Softclix lancing device kit (Black)
ACCU-CHEK® Guide Mic-Retail care kit * (see above for billing)	ACCU-CHEK® Fastclix lancing device kit
Test Strips	Control Solutions
ACCU-CHEK® AVIVA PLUS 50 ct test strips	ACCU-CHEK® Aviva glucose control solution (2 levels)
ACCU-CHEK® SMARTVIEW® 50 ct test strips	ACCU-CHEK® SmartView glucose control solution (1 level)
ACCU-CHEK® Guide 50 ct test strips	ACCU-CHEK® Guide 2-Level control solution (2 levels)
ACCU-CHEK® Guide 100 ct test strips	
Lancets	
ACCU-CHEK® Softclix 100 ct Lancets	
ACCU-CHEK® Fastclix 102 ct Lancets	